Scientists test new pill cocktail in fight against tough leukemia
NCT ID NCT04872790
Summary
This early-stage study is testing the safety and best dose of a new combination of oral pills (venetoclax and dasatinib) for adults with a specific, aggressive type of blood cancer called Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) or mixed phenotype acute leukemia (MPAL). The goal is to see if adding venetoclax to standard drugs helps control the disease better. The study will enroll about 20 adults who are newly diagnosed or whose cancer has returned.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED PHENOTYPE ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.